MARKET

VTVT

VTVT

Vtv Therapeutics
NASDAQ
28.21
0.00
0.00%
Opening 09:30 05/21 EDT
OPEN
--
PREV CLOSE
27.90
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
39.60
52 WEEK LOW
7.38
MARKET CAP
84.92M
P/E (TTM)
-3.2203
1D
5D
1M
3M
1Y
5Y
Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Pancreatic Cancer; Azeliragon Was Discovered By And Originally Under Development For Alzheimer's Disease By vtv Therapeutics, Which Cantex Licensed Worldwide Rights
FDA grants Orphan Drug Designation to Cantex Pharmaceuticals' azeliragon for the treatment of pancreatic cancer. Cantex is a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening conditions. The company's pill is well-tolerated once-a-day.
Benzinga · 21h ago
Weekly Report: what happened at VTVT last week (0513-0517)?
Weekly Report · 1d ago
Weekly Report: what happened at VTVT last week (0506-0510)?
Weekly Report · 05/13 12:30
vTv Therapeutics Inc. Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/10 15:56
VTVT Stock Earnings: vTv Therapeutics Reported Results for Q1 2024
VTv Therapeutics just reported results for the first quarter of 2024. The company reported earnings per share of -$1.17 and revenue of $1.00 million. InvestorPlace Earnings is a project that automates coverage of quarterly earnings reports.
Investorplace · 05/10 02:57
vTv Therapeutics Q1 EPS $(1.17) Up From $(2.40) YoY, Sales $1.00M
Benzinga · 05/09 22:08
vTv Therapeutics GAAP EPS of -$1.17, revenue of $1M
Seeking Alpha · 05/09 21:37
VTV THERAPEUTICS INC - NET LOSS ATTRIBUTABLE TO VTV SHAREHOLDERS FOR THREE MONTHS ENDED MARCH 31, 2024, WAS $4.9 MLN OR $1.17 PER BASIC SHARE
Reuters · 05/09 20:51
More
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.

Webull offers vTv Therapeutics Inc stock information, including NASDAQ: VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.